Baixar PDF
Artigo anterior
Voltar à página
Artigo seguinte
If you have problems to see the content please click here
Outros usuários também visualizaram estes artigos
PRELIMINARY RESULTS OF DARATUMUMAB, CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE: A QUADRUPLET INTENSIED TREATMENT FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) TRANSPLANT ELIGIBLE (TE) PATIENTS
E.Q. Crusoé; M.A. Salvino; S.Q. Silva; H.H.M. Santos; A.S. Santos; A.M. Almeida; L.O. Vieira; C.A. Fonseca; L.F. Lucas; J.S. Leal; M.M. Santos; J.A. Santos; E. Adorno; V.T.M. Hungria; M.G.B. Arruda;
Hematol Transfus Cell Ther. 2020;42 Supl 2:273
PRELIMINARY RESULTS OF DARATUMUMAB, CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE: A QUADRUPLET INTENSIED TREATMENT FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) TRANSPLANT ELIGIBLE (TE) PATIENTS
E.Q. Crusoé; M.A. Salvino; H.H.M. Santos; A.S. Santos; A.M. Almeida; C.A. Fonseca; J.S. Leal; J.A. Santos; V.T.M. Hungria; M.G.B. Arruda;
Hematol Transfus Cell Ther. 2020;42 Supl 2:273-4
Erratum on ``Eltrombopag as first-line treatment in severe aplastic anemia: a cost-effectiveness analysis from the Brazilian public healthcare system perspective¿
M.A. Salvino; C. Bonfim; R.T. Calado; H. Kim; J.F. Bertinato; P. Scheinberg;
Hematol Transfus Cell Ther. 2022;44:305